Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $87.81 USD
Change Today -0.47 / -0.53%
Volume 1.8M
As of 5:20 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

endo international plc (ENDP) Snapshot

Open
$88.02
Previous Close
$88.28
Day High
$88.83
Day Low
$87.15
52 Week High
03/20/15 - $93.03
52 Week Low
04/15/14 - $53.62
Market Cap
15.6B
Average Volume 10 Days
3.1M
EPS TTM
$1.76
Shares Outstanding
177.5M
EX-Date
--
P/E TM
50.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for ENDO INTERNATIONAL PLC (ENDP)

endo international plc (ENDP) Details

Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals segment provides various branded prescription products, including Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Fortesta Gel, Supprelin LA, Valstar, Vantas, Sumavel DosePro, Aveed, and Natesto to treat and manage pain and conditions in urology, endocrinology, and oncology. The U.S. Generic Pharmaceuticals segment offers products in the pain management, urology, CNS disorders, immunosuppression, oncology, women’s health, hypertension, generic lidocaine patch, and other markets. The Devices segment provides various medical devices comprising AMS 800 artificial urinary sphincters, AMS 700 MS series, Monarc subfascial hammock products, Elevate anterior and posterior pelvic floor repair systems, and GreenLight XPS laser systems in the areas of men’s and women’s pelvic health. The International Pharmaceuticals segment offers Dexedrine, Tridural, Metadol, Trandate, Pennsaid, and Plan B products in therapeutic areas, including attention deficit hyperactivity disorder, pain, urology, and allergy. It sells its branded pharmaceuticals and generics directly to large pharmacy chains; and through wholesale drug distributors to pharmacies, hospitals, governmental agencies, and physicians. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

5,062 Employees
Last Reported Date: 03/2/15
Founded in 1920

endo international plc (ENDP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $4.3M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $157.0K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $562.0K
Special Advisor to the Chief Executive Office...
Total Annual Compensation: $270.8K
Compensation as of Fiscal Year 2013.

endo international plc (ENDP) Key Developments

Endo International Launches Nasal Gel Testosterone Treatment

Endo International (ENDP) announced that it launched Natesto. The company noted the nasal gel was approved by the Food and Drug Administration in May 2014 for adult men with deficiency or absence of endogenous testosterone, including conditions both congenital or acquired. Endo also makes and sells other testosterone gels and implantable testosterone pellets, but it said the nasal gel reduces the risk of transference via intranasal application. The company said it obtained rights to the nasal gel for sale in the U.S. and Mexico from Trimel Pharmaceuticals for $25 million, plus additional payments related to regulatory and sales milestones.

Endo International Mulls Acquisition

Endo International plc (NasdaqGS:ENDP) is seeking acquisition. ''While we are disappointed with this outcome, we have been and will continue to be disciplined in our approach to potential acquisitions,'' Endo said in a statement, adding that it will focus on other acquisition opportunities and organic growth. ''We would like to wish Salix and Valeant continued success as they move forward with their transaction,'' Endo International said.

Endo International plc Presents at Barclays Global Healthcare Conference, Mar-12-2015 02:05 PM

Endo International plc Presents at Barclays Global Healthcare Conference, Mar-12-2015 02:05 PM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Rajiv Kanishka Liyanaarchchie De Silva, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $87.81 USD -0.47

ENDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $166.66 USD +0.01
Edwards Lifesciences Corp $141.90 USD -0.35
Intuitive Surgical Inc $498.99 USD +3.76
Mallinckrodt PLC $126.78 USD +0.12
UCB SA €67.62 EUR -0.63
View Industry Companies
 

Industry Analysis

ENDP

Industry Average

Valuation ENDP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.7x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit www.endo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.